Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
SolarEdge (SEDG) and Teva (TEVA) are Blowouts!
by Brian Bolan
One stock is being blown off the books and one had a blow out earnings report.
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
by Zacks Equity Research
Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.
Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down
by Zacks Equity Research
Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.
Teva (TEVA) Q2 Earnings and Sales Miss, Shares Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) second quarter earnings and revenue missed estimates. The company has also lowered its earnings and revenue guidance for 2017.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?
by Zacks Equity Research
While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker, Actavis related to its key cancer drug, Alimta (pemetrexed disodium).
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) and Korean partner Celltrion, Inc., announced that the FDA has accepted for review their Biologics License Application (BLA) for CT-P10, a proposed biosimilar to Roche Holding AG's (RHHBY) Rituxan (rituximab).
Alder's Shares Dip Despite Positive Migraine Trial Results
by Zacks Equity Research
Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.
Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.
Allergan Continues to Focus on Acquisitions and Branded Unit
by Zacks Equity Research
We issued an updated research report on Allergan plc (AGN) on Jun 23.
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Teva Migraine Candidate Succeeds in Second Phase III Study
by Zacks Equity Research
Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.
Regeneron Announces Positive Data on Carcinoma Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).
Teva's Migraine Candidate TEV-48125 Positive in Phase III
by Zacks Equity Research
Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.